<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adhav, Anmol</style></author><author><style face="normal" font="default" size="100%">Harne, Shrikant</style></author><author><style face="normal" font="default" size="100%">Bhide, Amey</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Gayathri, Pananghat</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanistic insights into enzymatic catalysis by trehalase from the insect gut endosymbiont Enterobacter cloacae</style></title><secondary-title><style face="normal" font="default" size="100%">FEBS Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Enterobacter cloacae</style></keyword><keyword><style  face="normal" font="default" size="100%">Plutella xylostella</style></keyword><keyword><style  face="normal" font="default" size="100%">structural analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">trehalase</style></keyword><keyword><style  face="normal" font="default" size="100%">validoxylamine A</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAY</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">286</style></volume><pages><style face="normal" font="default" size="100%">1700-1716</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Energy metabolism in the diamondback moth Plutella xylostella is facilitated by trehalase, an enzyme which assists in trehalose hydrolysis, from the predominant gut bacterium Enterobacter cloacae. We report the biochemical and structural characterization of recombinant trehalase from E. cloacae (Px_EclTre). Px_EclTre showed K-M of 1.47 (+/- 0.05) mm, k(cat) of 6254.72 min(-1) and V-max 0.2 (+/- 0.002) mm center dot min(-1) at 55 degrees C and acidic pH. Crystal structures of Px_EclTre were determined in the ligand-free form and bound to the inhibitor Validoxylamine A. The crystal structure of the ligand-free form, unavailable until now for any other bacterial trehalases, enabled us to delineate the conformational changes accompanying ligand binding in trehalases. Multiple salt bridges were identified that potentially facilitated closure of a hood over the substrate-binding site. A cluster of five tryptophans lined the -1 substrate-binding subsite, interacted with crucial active site residues and contributed to both trehalase activity and stability. The importance of these residues in enzyme activity was further validated by mutagenesis studies. Many of these identified residues form part of signature motifs and other conserved sequences in trehalases. The structure analysis thus led to the assignment of the functional role to these conserved residues. This information can be further explored for the design of effective inhibitors against trehalases.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;4.739&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Trinkl, Johanna</style></author><author><style face="normal" font="default" size="100%">Haugeneder, Annika</style></author><author><style face="normal" font="default" size="100%">Haertl, Katja</style></author><author><style face="normal" font="default" size="100%">Franz-Oberdorf, Katrin</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Hoffmann, Thomas</style></author><author><style face="normal" font="default" size="100%">Schwab, Wilfried</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Semirational design and engineering of grapevine glucosyltransferases for enhanced activity and modified product selectivity</style></title><secondary-title><style face="normal" font="default" size="100%">Glycobiology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">flavonol</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycosyltransferase</style></keyword><keyword><style  face="normal" font="default" size="100%">in silico analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutagenesis</style></keyword><keyword><style  face="normal" font="default" size="100%">selectivity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">NOV</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">29</style></volume><pages><style face="normal" font="default" size="100%">765-775</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Uridine diphosphate-dependent glycosyltransferases (UGTs) catalyze the transfer of a diversity of sugars to several acceptor molecules and often exhibit distinct substrate specificity. Modulation of glycosyltransferases for increased catalytic activity and altered substrate or product specificity are the key manipulations for the biotechnological use of glycosyltransferases in various biosynthetic processes. Here, we have engineered the binding pocket of three previously characterized Vitis vinifera glycosyltransferases, UGT88F12, UGT72B27 and UGT92G6, by structure-guided in silico mutagenesis to facilitate the interactions of active site residues with flavonol glucosides and thus modify substrate specificity and activity. Site-directed mutagenesis at selected sites, followed with liquid chromatography-mass spectrometry based activity assays, exhibited that mutant UGTs were altered in product selectivity and activity as compared to the wild-type enzymes. Mutant UGTs produced larger amounts of flavonol di-monosaccharide glucosides, which imply that the mutations led to structural changes that increased the volume of the binding pocket to accommodate a larger substrate and to release larger products at ease. Mutants showed increased activity and modified product specificity. Thus, structure-based systematic mutations of the amino acid residues in the binding pocket can be explored for the generation of engineered UGTs for diverse biotechnological applications.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;3.664&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naushin, Salwa</style></author><author><style face="normal" font="default" size="100%">Sardana, Viren</style></author><author><style face="normal" font="default" size="100%">Ujjainiya, Rajat</style></author><author><style face="normal" font="default" size="100%">Bhatheja, Nitin</style></author><author><style face="normal" font="default" size="100%">Kutum, Rintu</style></author><author><style face="normal" font="default" size="100%">Bhaskar, Akash Kumar</style></author><author><style face="normal" font="default" size="100%">Pradhan, Shalini</style></author><author><style face="normal" font="default" size="100%">Prakash, Satyartha</style></author><author><style face="normal" font="default" size="100%">Khan, Raju</style></author><author><style face="normal" font="default" size="100%">Rawat, Birendra Singh</style></author><author><style face="normal" font="default" size="100%">Tallapaka, Karthik Bharadwaj</style></author><author><style face="normal" font="default" size="100%">Anumalla, Mahesh</style></author><author><style face="normal" font="default" size="100%">Chandak, Giriraj Ratan</style></author><author><style face="normal" font="default" size="100%">Lahiri, Amit</style></author><author><style face="normal" font="default" size="100%">Kar, Susanta</style></author><author><style face="normal" font="default" size="100%">Mulay, Shrikant Ramesh</style></author><author><style face="normal" font="default" size="100%">Mugale, Madhav Nilakanth</style></author><author><style face="normal" font="default" size="100%">Srivastava, Mrigank</style></author><author><style face="normal" font="default" size="100%">Khan, Shaziya</style></author><author><style face="normal" font="default" size="100%">Srivastava, Anjali</style></author><author><style face="normal" font="default" size="100%">Tomar, Bhawana</style></author><author><style face="normal" font="default" size="100%">Veerapandian, Murugan</style></author><author><style face="normal" font="default" size="100%">Venkatachalam, Ganesh</style></author><author><style face="normal" font="default" size="100%">Vijayakumar, Selvamani Raja</style></author><author><style face="normal" font="default" size="100%">Agarwal, Ajay</style></author><author><style face="normal" font="default" size="100%">Gupta, Dinesh</style></author><author><style face="normal" font="default" size="100%">Halami, Prakash M.</style></author><author><style face="normal" font="default" size="100%">Peddha, Muthukumar Serva</style></author><author><style face="normal" font="default" size="100%">Sundaram, Gopinath M.</style></author><author><style face="normal" font="default" size="100%">Veeranna, Ravindra P.</style></author><author><style face="normal" font="default" size="100%">Pal, Anirban</style></author><author><style face="normal" font="default" size="100%">Agarwal, Vinay Kumar</style></author><author><style face="normal" font="default" size="100%">Maurya, Anil Ku</style></author><author><style face="normal" font="default" size="100%">Singh, Ranvijay Kumar</style></author><author><style face="normal" font="default" size="100%">Raman, Ashok Kumar</style></author><author><style face="normal" font="default" size="100%">Anandasadagopan, Suresh Kumar</style></author><author><style face="normal" font="default" size="100%">Karuppanan, Parimala</style></author><author><style face="normal" font="default" size="100%">Venkatesan, Subramanian</style></author><author><style face="normal" font="default" size="100%">Sardana, Harish Kumar</style></author><author><style face="normal" font="default" size="100%">Kothari, Anamika</style></author><author><style face="normal" font="default" size="100%">Jain, Rishabh</style></author><author><style face="normal" font="default" size="100%">Thakur, Anupama</style></author><author><style face="normal" font="default" size="100%">Parihar, Devendra Singh</style></author><author><style face="normal" font="default" size="100%">Saifi, Anas</style></author><author><style face="normal" font="default" size="100%">Kaur, Jasleen</style></author><author><style face="normal" font="default" size="100%">Kumar, Virendra</style></author><author><style face="normal" font="default" size="100%">Mishra, Avinash</style></author><author><style face="normal" font="default" size="100%">Gogeri, Iranna</style></author><author><style face="normal" font="default" size="100%">Rayasam, Geethavani</style></author><author><style face="normal" font="default" size="100%">Singh, Praveen</style></author><author><style face="normal" font="default" size="100%">Chakraborty, Rahul</style></author><author><style face="normal" font="default" size="100%">Chaturvedi, Gaura</style></author><author><style face="normal" font="default" size="100%">Karunakar, Pinreddy</style></author><author><style face="normal" font="default" size="100%">Yadav, Rohit</style></author><author><style face="normal" font="default" size="100%">Singhmar, Sunanda</style></author><author><style face="normal" font="default" size="100%">Singh, Dayanidhi</style></author><author><style face="normal" font="default" size="100%">Sarkar, Sharmistha</style></author><author><style face="normal" font="default" size="100%">Bhattacharya, Purbasha</style></author><author><style face="normal" font="default" size="100%">Acharya, Sundaram</style></author><author><style face="normal" font="default" size="100%">Singh, Vandana</style></author><author><style face="normal" font="default" size="100%">Verma, Shweta</style></author><author><style face="normal" font="default" size="100%">Soni, Drishti</style></author><author><style face="normal" font="default" size="100%">Seth, Surabhi</style></author><author><style face="normal" font="default" size="100%">Vashisht, Sakshi</style></author><author><style face="normal" font="default" size="100%">Thakran, Sarita</style></author><author><style face="normal" font="default" size="100%">Fatima, Firdaus</style></author><author><style face="normal" font="default" size="100%">Singh, Akash Pratap</style></author><author><style face="normal" font="default" size="100%">Sharma, Akanksha</style></author><author><style face="normal" font="default" size="100%">Sharma, Babita</style></author><author><style face="normal" font="default" size="100%">Subramanian, Manikandan</style></author><author><style face="normal" font="default" size="100%">Padwad, Yogendra S.</style></author><author><style face="normal" font="default" size="100%">Hallan, Vipin</style></author><author><style face="normal" font="default" size="100%">Patial, Vikram</style></author><author><style face="normal" font="default" size="100%">Singh, Damanpreet</style></author><author><style face="normal" font="default" size="100%">Tripude, Narendra Vijay</style></author><author><style face="normal" font="default" size="100%">Chakrabarti, Partha</style></author><author><style face="normal" font="default" size="100%">Maity, Sujay Krishna</style></author><author><style face="normal" font="default" size="100%">Ganguly, Dipyaman</style></author><author><style face="normal" font="default" size="100%">Sarkar, Jit</style></author><author><style face="normal" font="default" size="100%">Ramakrishna, Sistla</style></author><author><style face="normal" font="default" size="100%">Kumar, Balthu Narender</style></author><author><style face="normal" font="default" size="100%">Kumar, Kiran A.</style></author><author><style face="normal" font="default" size="100%">Gandhi, Sumit G.</style></author><author><style face="normal" font="default" size="100%">Jamwal, Piyush Singh</style></author><author><style face="normal" font="default" size="100%">Chouhan, Rekha</style></author><author><style face="normal" font="default" size="100%">Jamwal, Vijay Lakshmi</style></author><author><style face="normal" font="default" size="100%">Kapoor, Nitika</style></author><author><style face="normal" font="default" size="100%">Ghosh, Debashish</style></author><author><style face="normal" font="default" size="100%">Thakkar, Ghanshyam</style></author><author><style face="normal" font="default" size="100%">Subudhi, Umakanta</style></author><author><style face="normal" font="default" size="100%">Sen, Pradip</style></author><author><style face="normal" font="default" size="100%">Chaudhury, Saumya Ray</style></author><author><style face="normal" font="default" size="100%">Kumar, Rashmi</style></author><author><style face="normal" font="default" size="100%">Gupta, Pawan</style></author><author><style face="normal" font="default" size="100%">Tuli, Amit</style></author><author><style face="normal" font="default" size="100%">Sharma, Deepak</style></author><author><style face="normal" font="default" size="100%">Ringe, Rajesh P.</style></author><author><style face="normal" font="default" size="100%">Amarnarayan, D.</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Shanmugam, Dhansekaran</style></author><author><style face="normal" font="default" size="100%">Dharne, Mahesh S.</style></author><author><style face="normal" font="default" size="100%">Dastager, Sayed G.</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Patil, Amita P.</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin N.</style></author><author><style face="normal" font="default" size="100%">Khan, Abujunaid Habib</style></author><author><style face="normal" font="default" size="100%">Wagh, Vasudev</style></author><author><style face="normal" font="default" size="100%">Yadav, Rakesh Kumar</style></author><author><style face="normal" font="default" size="100%">Khilari, Ajinkya</style></author><author><style face="normal" font="default" size="100%">Bhadange, Mayuri</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Arvindkumar H.</style></author><author><style face="normal" font="default" size="100%">Kulsange, Shabda E.</style></author><author><style face="normal" font="default" size="100%">Khairnar, Krishna</style></author><author><style face="normal" font="default" size="100%">Paranjape, Shilpa</style></author><author><style face="normal" font="default" size="100%">Kalita, Jatin</style></author><author><style face="normal" font="default" size="100%">Sastry, Narahari G.</style></author><author><style face="normal" font="default" size="100%">Phukan, Tridip</style></author><author><style face="normal" font="default" size="100%">Manna, Prasenjit</style></author><author><style face="normal" font="default" size="100%">Romi, Wahengbam</style></author><author><style face="normal" font="default" size="100%">Bharali, Pankaj</style></author><author><style face="normal" font="default" size="100%">Ozah, Dibyajyoti</style></author><author><style face="normal" font="default" size="100%">Sahu, Ravi Kumar</style></author><author><style face="normal" font="default" size="100%">Babu, Elapavalooru Vssk</style></author><author><style face="normal" font="default" size="100%">Sukumaran, Rajeev</style></author><author><style face="normal" font="default" size="100%">Nair, Aiswarya R.</style></author><author><style face="normal" font="default" size="100%">Valappil, Prajeesh Kooloth</style></author><author><style face="normal" font="default" size="100%">Puthiyamadam, Anoop</style></author><author><style face="normal" font="default" size="100%">Velayudhanpillai, Adarsh</style></author><author><style face="normal" font="default" size="100%">Chodankar, Kalpana</style></author><author><style face="normal" font="default" size="100%">Damare, Samir</style></author><author><style face="normal" font="default" size="100%">Madhavi, Yennapu</style></author><author><style face="normal" font="default" size="100%">Aggarwal, Ved Varun</style></author><author><style face="normal" font="default" size="100%">Dahiya, Sumit</style></author><author><style face="normal" font="default" size="100%">Agrawal, Anurag</style></author><author><style face="normal" font="default" size="100%">Dash, Debasis</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shantanu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Insights from a pan India Sero-epidemiological survey (Phenome-India Cohort) for SARS-CoV2</style></title><secondary-title><style face="normal" font="default" size="100%">eLife</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">APR </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">e66537</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, &amp;lt;0.0001), use of public transport (1.79, 1.43-2.24, &amp;lt;0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, &amp;lt;0.0001), and B blood group (1.36, 1.15-1.61, 0.001).&lt;/p&gt;</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">8.140</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, Prateek</style></author><author><style face="normal" font="default" size="100%">Ujjainiya, Rajat</style></author><author><style face="normal" font="default" size="100%">Prakash, Satyartha</style></author><author><style face="normal" font="default" size="100%">Naushin, Salwa</style></author><author><style face="normal" font="default" size="100%">Sardana, Viren</style></author><author><style face="normal" font="default" size="100%">Bhatheja, Nitin</style></author><author><style face="normal" font="default" size="100%">Singh, Ajay Pratap</style></author><author><style face="normal" font="default" size="100%">Barman, Joydeb</style></author><author><style face="normal" font="default" size="100%">Kumar, Kartik</style></author><author><style face="normal" font="default" size="100%">Gayali, Saurabh</style></author><author><style face="normal" font="default" size="100%">Khan, Raju</style></author><author><style face="normal" font="default" size="100%">Rawat, Birendra Singh</style></author><author><style face="normal" font="default" size="100%">Tallapaka, Karthik Bharadwaj</style></author><author><style face="normal" font="default" size="100%">Anumalla, Mahesh</style></author><author><style face="normal" font="default" size="100%">Lahiri, Amit</style></author><author><style face="normal" font="default" size="100%">Kar, Susanta</style></author><author><style face="normal" font="default" size="100%">Bhosale, Vivek</style></author><author><style face="normal" font="default" size="100%">Srivastava, Mrigank</style></author><author><style face="normal" font="default" size="100%">Mugale, Madhav Nilakanth</style></author><author><style face="normal" font="default" size="100%">Pandey, C. P.</style></author><author><style face="normal" font="default" size="100%">Khan, Shaziya</style></author><author><style face="normal" font="default" size="100%">Katiyar, Shivani</style></author><author><style face="normal" font="default" size="100%">Raj, Desh</style></author><author><style face="normal" font="default" size="100%">Ishteyaque, Sharmeen</style></author><author><style face="normal" font="default" size="100%">Khanka, Sonu</style></author><author><style face="normal" font="default" size="100%">Rani, Ankita</style></author><author><style face="normal" font="default" size="100%">Promila</style></author><author><style face="normal" font="default" size="100%">Sharma, Jyotsna</style></author><author><style face="normal" font="default" size="100%">Seth, Anuradha</style></author><author><style face="normal" font="default" size="100%">Dutta, Mukul</style></author><author><style face="normal" font="default" size="100%">Saurabh, Nishant</style></author><author><style face="normal" font="default" size="100%">Veerapandian, Murugan</style></author><author><style face="normal" font="default" size="100%">Venkatachalam, Ganesh</style></author><author><style face="normal" font="default" size="100%">Bansal, Deepak</style></author><author><style face="normal" font="default" size="100%">Gupta, Dinesh</style></author><author><style face="normal" font="default" size="100%">Halami, Prakash M.</style></author><author><style face="normal" font="default" size="100%">Peddha, Muthukumar Serva</style></author><author><style face="normal" font="default" size="100%">Veeranna, Ravindra P.</style></author><author><style face="normal" font="default" size="100%">Pal, Anirban</style></author><author><style face="normal" font="default" size="100%">Singh, Ranvijay Kumar</style></author><author><style face="normal" font="default" size="100%">Anandasadagopan, Suresh Kumar</style></author><author><style face="normal" font="default" size="100%">Karuppanan, Parimala</style></author><author><style face="normal" font="default" size="100%">Rahman, Syed Nasar</style></author><author><style face="normal" font="default" size="100%">Selvakumar, Gopika</style></author><author><style face="normal" font="default" size="100%">Venkatesan, Subramanian</style></author><author><style face="normal" font="default" size="100%">Karmakar, Malay Kumar</style></author><author><style face="normal" font="default" size="100%">Sardana, Harish Kumar</style></author><author><style face="normal" font="default" size="100%">Kothari, Anamika</style></author><author><style face="normal" font="default" size="100%">Parihar, Devendra Singh</style></author><author><style face="normal" font="default" size="100%">Thakur, Anupma</style></author><author><style face="normal" font="default" size="100%">Saifi, Anas</style></author><author><style face="normal" font="default" size="100%">Gupta, Naman</style></author><author><style face="normal" font="default" size="100%">Singh, Yogita</style></author><author><style face="normal" font="default" size="100%">Reddu, Ritu</style></author><author><style face="normal" font="default" size="100%">Gautam, Rizul</style></author><author><style face="normal" font="default" size="100%">Mishra, Anuj</style></author><author><style face="normal" font="default" size="100%">Mishra, Avinash</style></author><author><style face="normal" font="default" size="100%">Gogeri, Iranna</style></author><author><style face="normal" font="default" size="100%">Rayasam, Geethavani</style></author><author><style face="normal" font="default" size="100%">Padwad, Yogendra</style></author><author><style face="normal" font="default" size="100%">Patial, Vikram</style></author><author><style face="normal" font="default" size="100%">Hallan, Vipin</style></author><author><style face="normal" font="default" size="100%">Singh, Damanpreet</style></author><author><style face="normal" font="default" size="100%">Tirpude, Narendra</style></author><author><style face="normal" font="default" size="100%">Chakrabarti, Partha</style></author><author><style face="normal" font="default" size="100%">Maity, Sujay Krishna</style></author><author><style face="normal" font="default" size="100%">Ganguly, Dipyaman</style></author><author><style face="normal" font="default" size="100%">Sistla, Ramakrishna</style></author><author><style face="normal" font="default" size="100%">Balthu, Narender Kumar</style></author><author><style face="normal" font="default" size="100%">Kumar, Kiran A.</style></author><author><style face="normal" font="default" size="100%">Ranjith, Siva</style></author><author><style face="normal" font="default" size="100%">Kumar, B. Vijay</style></author><author><style face="normal" font="default" size="100%">Jamwal, Piyush Singh</style></author><author><style face="normal" font="default" size="100%">Wali, Anshu</style></author><author><style face="normal" font="default" size="100%">Ahmed, Sajad</style></author><author><style face="normal" font="default" size="100%">Chouhan, Rekha</style></author><author><style face="normal" font="default" size="100%">Gandhi, Sumit G.</style></author><author><style face="normal" font="default" size="100%">Sharma, Nancy</style></author><author><style face="normal" font="default" size="100%">Rai, Garima</style></author><author><style face="normal" font="default" size="100%">Irshad, Faisal</style></author><author><style face="normal" font="default" size="100%">Jamwal, Vijay Lakshmi</style></author><author><style face="normal" font="default" size="100%">Paddar, Masroor Ahmad</style></author><author><style face="normal" font="default" size="100%">Khan, Sameer Ullah</style></author><author><style face="normal" font="default" size="100%">Malik, Fayaz</style></author><author><style face="normal" font="default" size="100%">Ghosh, Debashish</style></author><author><style face="normal" font="default" size="100%">Thakkar, Ghanshyam</style></author><author><style face="normal" font="default" size="100%">Barik, S. K.</style></author><author><style face="normal" font="default" size="100%">Tripathi, Prabhanshu</style></author><author><style face="normal" font="default" size="100%">Satija, Yatendra Kumar</style></author><author><style face="normal" font="default" size="100%">Mohanty, Sneha</style></author><author><style face="normal" font="default" size="100%">Khan, Md Tauseef</style></author><author><style face="normal" font="default" size="100%">Subudhi, Umakanta</style></author><author><style face="normal" font="default" size="100%">Sen, Pradip</style></author><author><style face="normal" font="default" size="100%">Kumar, Rashmi</style></author><author><style face="normal" font="default" size="100%">Bhardwaj, Anshu</style></author><author><style face="normal" font="default" size="100%">Gupta, Pawan</style></author><author><style face="normal" font="default" size="100%">Sharma, Deepak</style></author><author><style face="normal" font="default" size="100%">Tuli, Amit</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, Saumya Ray</style></author><author><style face="normal" font="default" size="100%">Krishnamurthi, Srinivasan</style></author><author><style face="normal" font="default" size="100%">Prakash, L.</style></author><author><style face="normal" font="default" size="100%">Rao, V. Ch</style></author><author><style face="normal" font="default" size="100%">Singh, B. N.</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Arvindkumar</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Meera</style></author><author><style face="normal" font="default" size="100%">Bhadange, Mayuri</style></author><author><style face="normal" font="default" size="100%">Likhitkar, Bhagyashree</style></author><author><style face="normal" font="default" size="100%">Mohite, Sharada</style></author><author><style face="normal" font="default" size="100%">Patil, Yogita</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Pandya, Vaibhav</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin</style></author><author><style face="normal" font="default" size="100%">Patil, Amita</style></author><author><style face="normal" font="default" size="100%">Samson, Rachel</style></author><author><style face="normal" font="default" size="100%">Vare, Tejas</style></author><author><style face="normal" font="default" size="100%">Dharne, Mahesh</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin</style></author><author><style face="normal" font="default" size="100%">Paranjape, Shilpa</style></author><author><style face="normal" font="default" size="100%">Sastry, G. Narahari</style></author><author><style face="normal" font="default" size="100%">Kalita, Jatin</style></author><author><style face="normal" font="default" size="100%">Phukan, Tridip</style></author><author><style face="normal" font="default" size="100%">Manna, Prasenjit</style></author><author><style face="normal" font="default" size="100%">Romi, Wahengbam</style></author><author><style face="normal" font="default" size="100%">Bharali, Pankaj</style></author><author><style face="normal" font="default" size="100%">Ozah, Dibyajyoti</style></author><author><style face="normal" font="default" size="100%">Sahu, RaviKumar</style></author><author><style face="normal" font="default" size="100%">Dutta, Prachurjya</style></author><author><style face="normal" font="default" size="100%">Singh, Moirangthem Goutam</style></author><author><style face="normal" font="default" size="100%">Gogoi, Gayatri</style></author><author><style face="normal" font="default" size="100%">Tapadar, Yasmin Begam</style></author><author><style face="normal" font="default" size="100%">Babu, Elapavalooru V. S. S. K.</style></author><author><style face="normal" font="default" size="100%">Sukumaran, Rajeev K.</style></author><author><style face="normal" font="default" size="100%">Nair, Aishwarya R.</style></author><author><style face="normal" font="default" size="100%">Puthiyamadam, Anoop</style></author><author><style face="normal" font="default" size="100%">Valappil, Prajeesh Kooloth</style></author><author><style face="normal" font="default" size="100%">Prasannakumari, Adrash Velayudhan Pillai</style></author><author><style face="normal" font="default" size="100%">Chodankar, Kalpana</style></author><author><style face="normal" font="default" size="100%">Damare, Samir</style></author><author><style face="normal" font="default" size="100%">Agrawal, Ved Varun</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Kumardeep</style></author><author><style face="normal" font="default" size="100%">Agrawal, Anurag</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shantanu</style></author><author><style face="normal" font="default" size="100%">Dash, Debasis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys</style></title><secondary-title><style face="normal" font="default" size="100%">Computers in Biology and Medicine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BBV152</style></keyword><keyword><style  face="normal" font="default" size="100%">Covaxin</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Ensemble methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">146</style></volume><pages><style face="normal" font="default" size="100%">105419</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the vaccine effectiveness. Asymptomatic breakthrough infections have been a major problem in assessing vaccine effectiveness in populations globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines since whole virion vaccines generate antibodies against all the viral proteins. Here, we show how a statistical and machine learning (ML) based approach can be used to discriminate between SARS-CoV-2 infection and immune response to an inactivated whole virion vaccine (BBV152, Covaxin). For this, we assessed serial data on antibodies against Spike and Nucleocapsid antigens, along with age, sex, number of doses taken, and days since last dose, for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, our ensemble ML model classified 724 to be infected. For method validation, we determined the relative ability of a random subset of samples to neutralize Delta versus wild-type strain using a surrogate neutralization assay. We worked on the premise that antibodies generated by a whole virion vaccine would neutralize wild type more efficiently than delta strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, neutralization against Delta strain was more effective, indicating infection. We found 71.8% subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period. Our approach will help in real-world vaccine effectiveness assessments where whole virion vaccines are commonly used.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	6.698&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghosh, Debajeet</style></author><author><style face="normal" font="default" size="100%">Bansode, Sneha</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Kolte, Baban</style></author><author><style face="normal" font="default" size="100%">Gacche, Rajesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular elucidation of pancreatic elastase inhibition by baicalein</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Biomolecular Structure &amp; Dynamics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Baicalein</style></keyword><keyword><style  face="normal" font="default" size="100%">elastase</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme inhibition</style></keyword><keyword><style  face="normal" font="default" size="100%">molecular interaction</style></keyword><keyword><style  face="normal" font="default" size="100%">sivelestat</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">40</style></volume><pages><style face="normal" font="default" size="100%">5759-5768</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The serine protease, elastase exists in various forms and plays diverse roles in the human body. Pharmacological inhibition of elastase has been investigated for its therapeutic role in managing conditions such as diabetes, pneumonia and arthritis. Sivelestat, a synthetic molecule, is the only elastase inhibitor to have been approved by any major drug regulatory authority (PMDA, in this case) - but still has failed to attain widespread clinical usage owing to its high price, cumbersome administration and obscure long-term safety profile. In order to find a relatively better-suited alternative, screening was conducted using plant flavonoids, which yielded baicalein, a molecule that showed robust inhibition against Pancreatic Elastase inhibition (IC50: 3.53 mu M). Other than having a considerably lower IC(50)than sivelestat, baicalein is also cheaper, safer and easier to administer. While MicroScale Thermophoresis validated baicalein-elastase interaction, enzyme-kinetic studies, molecular docking and molecular dynamic simulation revealed the mode of inhibition to be non-competitive. Baicalein exhibited binding to a distinct allosteric site on the enzyme. The current study demonstrates the elastase inhibition properties of baicalein in an in-vitro and in-silico environment.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">13</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	5.235&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bansode, Sneha</style></author><author><style face="normal" font="default" size="100%">Singh, Pawan Kumar</style></author><author><style face="normal" font="default" size="100%">Tellis, Meenakshi</style></author><author><style face="normal" font="default" size="100%">Chugh, Anita</style></author><author><style face="normal" font="default" size="100%">Deshmukh, Narendra</style></author><author><style face="normal" font="default" size="100%">Gupta, Mahesh</style></author><author><style face="normal" font="default" size="100%">Verma, Savita</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Dhruva</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comprehensive molecular and clinical investigation of approved Anti-HCV drugs repurposing against SARS-CoV-2 infection: a glaring gap between benchside and bedside medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antiviral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">daclatasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">ledipasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">sofosbuvir</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">515</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation. In this report, the anti-SARS-CoV-2 potential of anti-HCV drugs such as daclatasvir (DCV) or ledipasvir (LDP) in combination with sofosbuvir (SOF) was evaluated. The binding mode and higher affinity of these molecules with RNA-dependent-RNA-polymerase of SARS-CoV-2 were apparent by computational analysis. In vitro anti-SARS-CoV-2 activity depicted that SOF/DCV and SOF/LDP combination has IC50 of 1.8 and 2.0 mu M, respectively, comparable to remdesivir, an approved drug for COVID-19. Furthermore, the clinical trial was conducted in 183 mild COVID-19 patients for 14 days to check the efficacy and safety of SOF/DCV and SOF/LDP compared to standard of care (SOC) in a parallel-group, hybrid, individually randomized, controlled clinical study. The primary outcomes of the study suggested no significant difference in negativity after 3, 7 and 14 days in both treatments. None of the patients displayed any worsening in the disease severity, and no mortality was observed in the study. Although, the post hoc exploratory analysis indicated significant normalization of the pulse rate showed in SOF/DCV and SOF/LDP treatment vs. SOC. The current study highlights the limitations of bench side models in predicting the clinical efficacy of drugs that are planned for repurposing.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.961&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meena, Chhuttan L.</style></author><author><style face="normal" font="default" size="100%">Hingamire, Tejashri</style></author><author><style face="normal" font="default" size="100%">Gupta, Tanya</style></author><author><style face="normal" font="default" size="100%">Deshmukh, Bhagyashree</style></author><author><style face="normal" font="default" size="100%">Karmodiya, Krishanpal</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Shanmugam, Dhanasekaran</style></author><author><style face="normal" font="default" size="100%">Sanjayan, Gangadhar J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Histidinal-based potent antimalarial agents</style></title><secondary-title><style face="normal" font="default" size="100%">ChemMedChem</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style  face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style  face="normal" font="default" size="100%">digestive vacuole</style></keyword><keyword><style  face="normal" font="default" size="100%">docking</style></keyword><keyword><style  face="normal" font="default" size="100%">falcipains</style></keyword><keyword><style  face="normal" font="default" size="100%">falciparum</style></keyword><keyword><style  face="normal" font="default" size="100%">P</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAY </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Herein we report the synthesis and evaluation of peptide-histidinal conjugated drug scaffolds, which have the potential to target the hemoglobin-degrading proteases falcipain-2/3 from the human malaria parasite. Scaffolds with various substitutions were tested for antimalarial activity, and compounds 8 g, 8 h, and 15 exhibited EC50 values of similar to 0.018 mu M, similar to 0.069 mu M, and similar to 0.02 mu M, respectively. Structure-based docking studies on falcipain-2/3 proteases (PDB:2GHU and PDB:3BWK) revealed that compounds 8 g, 8 h, and 15 interact strongly with binding sites of falcipain-2/3 in a substrate-like manner. In silico ADME studies revealed that the molecules of interest showed no or minimal violations of drug-likeness parameters. Further, phenotypic assays revealed that compound 8 g and its biotinylated version inhibit hemoglobin degradation in the parasite food vacuole. The identification of falcipain-2/3 targeting potent inhibitors of the malaria parasite can serve as a starting point for the development of lead compounds as future antimalarial drug candidates.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	3.540&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tellis, Meenakshi</style></author><author><style face="normal" font="default" size="100%">Mohite, Sharada</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Trehalase inhibition in Helicoverpa armigera activates machinery for alternate energy acquisition</style></title><secondary-title><style face="normal" font="default" size="100%">JOURNAL OF BIOSCIENCES</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Energy metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">glucose</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptomics</style></keyword><keyword><style  face="normal" font="default" size="100%">trehalase</style></keyword><keyword><style  face="normal" font="default" size="100%">validamycin A</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">49</style></volume><pages><style face="normal" font="default" size="100%">74</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Indian&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;2.9&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ranawade, Preeti</style></author><author><style face="normal" font="default" size="100%">Sonwane, Babasaheb</style></author><author><style face="normal" font="default" size="100%">Bose, Ganesh</style></author><author><style face="normal" font="default" size="100%">Jadhav, Revati</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Mittal, Smriti</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integrative transcriptomics and metabolomics reveal distinct metabolic reprogramming in luminal and triple-negative breast cancer cells</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Omics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JAN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">aaiaf003</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Breast cancer subtypes exhibit significant molecular and metabolic heterogeneity, influencing their aggressiveness and therapeutic responses. Among them, triple-negative breast cancer (TNBC) is highly aggressive and often resistant to conventional therapies. To investigate the metabolic programming of this aggressiveness, we conducted an integrated transcriptomics and metabolomics analysis comparing the MCF-7 (luminal A, ER+/PR+) and MDA-MB-231 (TNBC) breast cancer cell lines. Transcriptome analysis of MCF-7 and MDA-MB-231 revealed the differential expression of genes involved in key metabolic pathways. Metabolomics data, further corroborated by transcriptomics, suggest pathway enrichment in beta-alanine, histidine, glutathione, nucleotide metabolism, and the tricarboxylic acid cycle. MDA-MB-231 cells displayed a metabolically aggressive phenotype with enhanced oxidative phosphorylation, redox adaptation, and nucleotide turnover. In contrast, MCF-7 cells showed a more regulated amino acid and redox metabolism profile. The integration of transcriptomic and metabolite profiles highlighted potential metabolic vulnerabilities in TNBC, offering insights into subtype-specific differences at the molecular level.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	2.4&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kataria, Priyanka</style></author><author><style face="normal" font="default" size="100%">Vairale, Shiva</style></author><author><style face="normal" font="default" size="100%">Mote, Chandrashekhar</style></author><author><style face="normal" font="default" size="100%">Joshi, Kaustubh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh J.</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok P.</style></author><author><style face="normal" font="default" size="100%">Kontham, Ravindar</style></author><author><style face="normal" font="default" size="100%">Agawane, Sachin B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel prodrug-inspired eugenol derivatives with enhanced bioavailability, anti-diabetic and anti-glycation efficacies</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Molecular Structure</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino acid conjugates</style></keyword><keyword><style  face="normal" font="default" size="100%">Antidiabetic activity</style></keyword><keyword><style  face="normal" font="default" size="100%">Bioavailability enhancement</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug design and synthesis</style></keyword><keyword><style  face="normal" font="default" size="100%">Eugenol analogs</style></keyword><keyword><style  face="normal" font="default" size="100%">In silico and in vitro studies</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">APR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">1357</style></volume><pages><style face="normal" font="default" size="100%">145175</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	In this study, we present the design, synthesis, and evaluation of novel eugenol analogs aimed to overcome its limited bioavailability due to insolubility in aqueous media. Thus, we re-engineered eugenol using prodruginspired structural modifications to improve pharmacokinetic properties. First, we structurally modified eugenol and synthesized its natural amino acid conjugates as esters and carbamates. These were prepared in NBoc protected, free amine, and HCl salt forms. These modifications are expected to improve the polarity and solubility of eugenol congeners in biological systems. They can also release the parent eugenol through enzymatic hydrolysis, enhancing its therapeutic potential. Next, we comprehensively screened for these derivatives through in silico studies followed by in vitro and in vivo assays. These include DPPH radical scavenging (IC50 range: 37.7 to 103.7 mu M), inhibition of (i) alpha-amylase (IC50 23.1 to 67.3 mu M), (ii) alpha-glucosidase (IC50 43.6 to 50.4 mu M), (iii) glycation (IC50 31.9 to 110.3 mu M) along with pharmacokinetic profiling and toxicity assessments. These experiments collectively demonstrated improved activity of eugenol analogs for several important parameters. Specifically, six analogs-epoxy eugenol (39), hydroxy eugenol (43), aspartate eugenol (26), isoleucinate eugenol (24), glutamate eugenol (37), and glutamate-salt eugenol (27) exhibited superior bioavailability, absorption, and distribution over to the parent compound eugenol. These analogs were found to be non-toxic and safe for oral administration. Overall, the study establishes a mechanistic and rational framework for modifying eugenol to overcome its inherent biopharmaceutical limitations, positioning them as promising candidates for treating diabetes and glycation-related conditions.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.7&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vare, Tejas</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Liao, Jieren</style></author><author><style face="normal" font="default" size="100%">Hoffmann, Thomas</style></author><author><style face="normal" font="default" size="100%">Schwab, Wilfried</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phenylpropanoid-specific glycosyltransferases from mango and their potential role in defense</style></title><secondary-title><style face="normal" font="default" size="100%">Plant Physiology and Biochemistry</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anthracnose</style></keyword><keyword><style  face="normal" font="default" size="100%">defense</style></keyword><keyword><style  face="normal" font="default" size="100%">Flavonoid</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycoconjugates</style></keyword><keyword><style  face="normal" font="default" size="100%">Uridine diphosphate-dependent glycosyl-transferase</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">232</style></volume><pages><style face="normal" font="default" size="100%">111137</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Alphonso mango (Mangifera indica cv. Alphonso) is a cornerstone of India's fruit industry due to its distinct aroma and shelf-life characteristics. The uridine diphosphate-dependent glycosyltransferases (UGTs) play a crucial role in stabilising aroma and defense-related specialised metabolites in fruits. The present study explores the potential role of UGTs during mango ripening and Colletotrichum gloeosporioides infection. Gene expression analysis indicated that UGTs showed dynamic expression in skin and pulp during ripening. Phylogenetic analysis revealed substrate-driven divergence of UGTs, with MiUGT92A14 and MiUGT95B15 forming distinct clades associated with flavonoid glycosylation. Recombinant UGTs showed a higher preference for UDP-glucose, which is corroborated by the high accumulation of UDP-glucose during ripening. Furthermore, it was observed that MiUGT92A14 prefers phenolic acids as substrates, while MiGT95B15 shows flavonoid specificity. Spore germination assays demonstrated that both aglycones and their glycosylated derivatives suppressed early fungal morphogenesis, supporting a role for UGT-mediated glycosylation in maintaining defense-related metabolites in a bioactive yet non-toxic form during fruit ripening. Additionally, Colletotrichum gloeosporioides inhibition assays demonstrated that glycosylated products of selected UGTs exhibited equal or enhanced antifungal activity compared with their aglycone forms, indicating that glycosylation promotes the safe accumulation of antifungal compounds by reducing aglycone toxicity to the plant. These findings suggest that glycosylation of specific metabolites is a key for ripening process and to potentiate defence against fungal pathogen.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	5.7&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gone, Nilu Vijay</style></author><author><style face="normal" font="default" size="100%">Sharma, Tanisha</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Upreti, Akshita</style></author><author><style face="normal" font="default" size="100%">Santra, Manas</style></author><author><style face="normal" font="default" size="100%">Sanjayan, Gangadhar J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Repurposed ciprofloxacin derivatives as potent autophagic-type anticancer agents</style></title><secondary-title><style face="normal" font="default" size="100%">Bioorganic &amp; Medicinal Chemistry Letters</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anticancer drugs</style></keyword><keyword><style  face="normal" font="default" size="100%">Autophagic cell death</style></keyword><keyword><style  face="normal" font="default" size="100%">ciprofloxacin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JAN </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">130</style></volume><pages><style face="normal" font="default" size="100%">130432</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	Drug repurposing - also known as drug repositioning is a proven strategy for identifying new therapeutic uses for existing and pre-approved drugs with considerable success in recent years. Herein, we report the discovery of a novel class of ciprofloxacin-amino acid conjugates that are dynamically potent against different cancer cell lines. Some of the molecules reported herein displayed a strong anti-proliferative effect on MCF-7 (IC50: 6 mu M). The most active anti-proliferative molecule of this series 7a suppressed the proliferation of HCT116, A549, and MDAMB-231 cancer cell lines. Furthermore, we established that the treatment with 7a leads to DNA damage-mediated autophagic cell death in cancer cells. Our findings suggest that appropriate derivatization of the ciprofloxacin drug can yield promising anti-cancer compounds in easy synthetic operations.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	2.2&lt;/p&gt;
</style></custom4></record></records></xml>